Colorectal cancer in women: Hormone replacement therapy and chemoprevention

Climacteric

Volumn 15, Issue 3, 2012, Pages 250-255

  Barnes, E L ^a   Long, M D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CANCER; CHEMOPREVENTION; COLON; COLORECTAL CANCER; HORMONE REPLACEMENT THERAPY; RECTAL CANCER

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; CALCIUM; CONJUGATED ESTROGEN; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FOLIC ACID; GESTAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADENOMATOUS POLYP; BILE ACID METABOLISM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CARDIOVASCULAR RISK; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; INTENTION TO TREAT ANALYSIS; MICROSATELLITE INSTABILITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECTUM ADENOMA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; UNITED STATES;

AGED; ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; RISK FACTORS; WOMEN'S HEALTH;

EID: 84861407761     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.659450     Document Type: Review

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
2. SEER cancer statistics review, 1973-2007. National Cancer Institute
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
4. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009;10:211-19
5. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A casecontrol study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7
6. Newcomb PA, Norfl eet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-5
7. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73
8. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8 (Pubitemid 30419092)
9. Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control 2005;16:965-73 (Pubitemid 41191421)
10. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5: 779-84 (Pubitemid 26346276)
11. Peipins LA, Newman B, Sandler RS. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997;6:671-5 (Pubitemid 27427621)
12. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45 (Pubitemid 351347060)
13. Wasif N, Etzioni D, Maggard MA, Tomlinson JS, Ko CY. Trends, patterns, and outcomes in the management of malignant colonic polyps in the general population of the United States. Cancer 2011;117:931-7
14. Huang CS, Farraye FA, Yang S, O'Brien MJ. The clinical signifi-cance of serrated polyps. Am J Gastroenterol 2011;106:229-40
15. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-100
16. Noffsinger AE, Hart J. Serrated adenoma: a distinct form of nonpolypoid colorectal neoplasia? Gastrointest Endosc Clin N Am 2010;20:543-63
17. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 2005;124:380-91 (Pubitemid 41232924)
18. Li D, Jin C, McCulloch C, et al. Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am JGastroenterol 2009;104:695-702
19. Lazarus R, Junttila OE, Karttunen TJ, Makinen MJ. The risk of metachronous neoplasia in patients with serrated adenoma. Am J Clin Pathol 2005;123:349-59 (Pubitemid 40315075)
20. Hiraoka S, Kato J, Fujiki S, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology 2010;139:1503-10
21. Schreiner MA, Weiss DG, Lieberman DA. Proximal and large hyperplastic and nondysplastic serrated polyps detected by colonoscopy are associated with neoplasia. Gastroenterology 2010;139: 1497-502
22. Pai RK, Hart J, Noffsinger AE. Sessile serrated adenomas strongly predispose to synchronous serrated polyps in non-syndromic patients. Histopathology 2010;56:581-8
23. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011;42:1-10
24. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30 (Pubitemid 44953403)
25. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004 (Pubitemid 38269276)
26. Ritenbaugh C, Stanford JL, Wu L, et al . Conjugated equine estrogens and colorectal cancer incidence and survival: the Women'sHealth Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17:2609-18
27. Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007;67:7534-9 (Pubitemid 47206584)
28. Delellis Henderson K, Duan L, Sullivan-Halley J, et al. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol 2010;171:415-25
29. Johnson JR, Lacey JV Jr, Lazovich D, et al . Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:196-203
30. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 2009;27:4542-7
31. Long MD, Martin CF, Galanko JA, Sandler RS. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am J Gastroenterol 2010;105:1843-50
32. LaCroix AZ, Chlebowski RT, Manson JE, et al . Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
33. Martin RM, Wheeler BW, Metcalfe C, Gunnell D. What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study. J Public Health (Oxf) 2010;32:555-64
34. Slattery ML, Potter JD, Curtin K, et al . Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instabilitypositive colon cancer. Cancer Res 2001;61:126-30 (Pubitemid 32095709)
35. Newcomb PA, Pocobelli G, Chia V. Why hormones protect against large bowel cancer: old ideas, new evidence. Adv Exp Med Biol 2008;617:259-69
36. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profi les that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 1985;75:185-91 (Pubitemid 15229323)
37. Ma J, Pollak MN, Giovannucci E, et al . Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5 (Pubitemid 29194048)
38. Saydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:412-18 (Pubitemid 36578478)
39. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 2005;14:1394-401 (Pubitemid 40807337)
40. Heald A, Selby PL, White A, Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 2000;183:593-600
41. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102 (Pubitemid 40365350)
42. Hing E, Brett KM. Changes in US prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108: 33-40 (Pubitemid 44336842)
43. Mishra G, Kok H, Ecob R, Cooper R, Hardy R, Kuh D. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British birth cohort. Am J Public Health 2006;96:1219-25 (Pubitemid 43967847)
44. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63:843-9 (Pubitemid 47237896)
45. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
46. French LM, Smith MA, Holtrop JS, Holmes-Rovner M. Hormone therapy after the Women's Health Initiative: a qualitative study. BMC Fam Pract 2006;7:61
47. Isaacs AJ, Drew SV, McPherson K. UK women doctors' use of hormone replacement therapy: 10-year follow-up. Climacteric 2005;8:154-61 (Pubitemid 40862991)